Pfizer tops Q4 hopes but lowers guidance for 2016

Revenue rose to US$14.05bn from US$13.1bn, also ahead of expectations of around US$13.6bn.

Pfizer is merging with Allergan

--- adds share price---

Pharma giant Pfizer (NYSE:PFE) beat expectations in its fourth quarter but tempered forecasts for the coming year.

The firm reported on Tuesday that fourth-quarter earnings halved compared to the previous year to US$61mln, or 10 cents per share (EPS), from US$1.22bn, or 19 cents per share.

However, the results include three months of legacy Hospira global operations, Pfizer said, and adjusted EPS was 53 cents per share, slightly ahead of hopes.

Revenue rose to US$14.05bn from US$13.1bn, also ahead of expectations of around US$13.6bn.

But for, 2016, the company said it expects "significant negative currency impact related to Venezuela."

Excluding the effects of its merger with Allergan, Pfizer said it expects adjusted EPS of US$2.20 to US$2.30, including the impact of currency headwinds, below estimates of US$2.38 per share.

Before the resumption of trading on Wall Street, shares were trading 1.7% lower in the pre-market trading, before nudging 0.77% higher in the regular session at US$30.21.

Quick facts: Pfizer

Price: 40.51 USD

Market: NYSE
Market Cap: $224.19 billion

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events


The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...



Corvus Gold looks to advance two interesting projects, North Bullfrog and...

Corvus Gold Inc (TSE: KOR) President and CEO Jeffery Pontius joined Steve Darling from Proactive at the Vancouver Resource Investment Conference with details about their two project, North Bullfrog and Mother Lode, both in Nevada. Pontius discussed the company's most recent news that Corvus has...

6 hours, 21 minutes ago

2 min read